Exelixis, Inc. $EXEL Shares Sold by Dimensional Fund Advisors LP

Key Points

• Dimensional Fund Advisors LP reduced its stake in Exelixis, Inc. by 16.9%, now owning approximately 4.23 million shares valued at around $156 million.
• Exelixis reported a quarterly earnings per share (EPS) of $0.75, exceeding analyst expectations, although revenue declined 10.8% year-over-year.
• Analysts have given Exelixis a Moderate Buy rating, with target prices ranging from $29 to $60, and the average target price currently set at $44.06.

Dimensional Fund Advisors LP reduced its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 16.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,235,375 shares of the biotechnology company's stock after selling 864,031 shares during the period. Dimensional Fund Advisors LP owned 1.54% of Exelixis worth $156,364,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in EXEL. Coppell Advisory Solutions LLC purchased a new stake in shares of Exelixis during the 4th quarter valued at about $25,000. Hemington Wealth Management raised its position in shares of Exelixis by 211.3% during the 1st quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company's stock valued at $28,000 after buying an additional 522 shares in the last quarter. Colonial Trust Co SC raised its position in shares of Exelixis by 616.9% during the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock valued at $30,000 after buying an additional 765 shares in the last quarter. Bartlett & CO. Wealth Management LLC purchased a new stake in shares of Exelixis during the 1st quarter valued at about $37,000. Finally, Costello Asset Management INC purchased a new stake in shares of Exelixis during the 1st quarter valued at about $39,000. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on EXEL. UBS Group set a $38.00 price target on shares of Exelixis and gave the company a "neutral" rating in a report on Wednesday, July 30th. Morgan Stanley cut their target price on Exelixis from $48.00 to $46.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 29th. Guggenheim reaffirmed a "buy" rating and set a $45.00 target price on shares of Exelixis in a research note on Tuesday, July 29th. Benchmark reaffirmed a "neutral" rating on shares of Exelixis in a research note on Monday, June 23rd. Finally, Jefferies Financial Group set a $50.00 target price on Exelixis and gave the company a "buy" rating in a research note on Tuesday, June 24th. Thirteen equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $44.06.

Insider Activity at Exelixis

In other Exelixis news, Director Jack L. Wyszomierski sold 7,535 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $43.09, for a total value of $324,683.15. Following the completion of the sale, the director directly owned 358,882 shares in the company, valued at $15,464,225.38. This trade represents a 2.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Sue Gail Eckhardt sold 18,838 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $42.74, for a total transaction of $805,136.12. Following the completion of the sale, the director owned 21,380 shares of the company's stock, valued at approximately $913,781.20. This trade represents a 46.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.85% of the stock is owned by company insiders.

Exelixis Price Performance

EXEL stock traded down $0.5550 during mid-day trading on Monday, reaching $38.0750. The company had a trading volume of 634,956 shares, compared to its average volume of 3,029,062. The company has a market capitalization of $10.25 billion, a PE ratio of 18.29, a price-to-earnings-growth ratio of 0.80 and a beta of 0.29. The firm has a 50 day moving average of $41.56 and a 200 day moving average of $39.36. Exelixis, Inc. has a 12 month low of $25.12 and a 12 month high of $49.62.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.12. The business had revenue of $568.26 million for the quarter, compared to analysts' expectations of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The business's revenue for the quarter was down 10.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.84 EPS. Exelixis has set its FY 2025 guidance at EPS. Analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.